‘First bionic eye’ retinal chip for blind to be available in 12 major markets in US later this year
July 1, 2013
The Argus II is the first and only “bionic eye” to be approved in countries throughout the world, including the U.S. It is used to treat patients with late stage retinitis pigmentosa (RP). Argus II was developed by Second Sight Medical Products, Inc.
Accepting patient consultations
In preparation for the launch of Argus II later this year, implanting centers, including UH, will soon begin to accept consultations for patients with RP.
UH is one of a select number of medical centers in 12 major markets in the nation, and the only one in Cleveland and the state of Ohio, chosen by Second Sight to offer the Argus II, which received FDA approval earlier this year.
How it works
Argus II works by converting video images captured by a miniature camera, housed in the patient’s glasses, into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes on the surface of the retina.
These pulses are intended to stimulate the retina’s remaining cells resulting in the corresponding perception of patterns of light in the brain. Patients then learn to interpret these visual patterns thereby regaining some visual function.
Contact information for patients wishing more information: